Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.
Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP
J Pain Symptom Manage 2003;25(6):512-518.
Review by
Erythropoietin, uncertainty principle and cancer related anaemia.
Clark O, Adams JR, Bennett CL, Djulbegovic B
BMC Cancer 2002;2(1):23.
Review by
Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales.
Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE
J Pain Symptom Manage 2002;24(6):547-561.
Review by Ford PA
Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
This is a well done study of anemic cancer patients on cisplatin chemotherapy that documents nicely that the best predictor of an ultimate good response... Read More
Recombinant human erythropoietin in pediatric oncology: a review.
Feusner J, Hastings C
Med Pediatr Oncol 2002;39(4):463-468.
Review by Ford PA
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659